Important to note that he said they plan to meet the FDA on the Revascor HLHS pathway next quarter, not next month.
Confirmation they've submitted the trial protocol for the Adult aGVhD trial and that is planned to enrol next quarter also.
Meeting FDA in March re pediatric aGVhD. Back trial currently screening and enrolling. Will receive FDA minutes re Revascor pathway in March.
He reckons they have the cash runway to complete Back & Adult aGVhD. Can't see that happening without a partnership but I think he's supremely confident that they have now provided a complete response to the CRL for ryoncil and that approval will trigger partnerships in other products.
Ann: Half Year Financial Results Presentation, page-20
-
- There are more pages in this discussion • 59 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
98.0¢ |
Change
-0.045(4.39%) |
Mkt cap ! $1.127B | |||
| Open | High | Low | Value | Volume |
| $1.03 | $1.04 | 97.0¢ | $6.805M | 6.806M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 80924 | 97.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 98.0¢ | 122816 | 32 |
View Market Depth
| Last trade - 15.01pm 24/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |